Rhenium-188 and copper-67 radiopharmaceuticals for the treatment of bladder cancer.
The favourable nuclear properties of copper-67 and rhenium-188 for therapeutic application are described, together with methods for the chemical synthesis of a number of derivatives. Survival from invasive bladder cancer has changed little over the past 20 years. The intravesicular administration of Cu-67 or Re-188 radiopharmaceuticals in the treatment of bladder cancer offers some promise for improvement in this situation.
Frier
Malcolm
M
Radiopharmacy Unit, Queens Medical Centre, Nottingham, UK. Malcolm.Frier@nottingham.ac.uk
D014408:Biomarkers, Tumor / Q000378:metabolism; D003301:Copper Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use; D007536:Isomerism; D018396:Mucin-1 / Q000378:metabolism; D016719:Radioimmunodetection; D016499:Radioimmunotherapy; D011868:Radioisotopes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D012211:Rhenium / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis / Q000532:radiotherapy*
D014408:Biomarkers, Tumor; D003301:Copper Radioisotopes; D018796:Immunoconjugates; D018396:Mucin-1; D011868:Radioisotopes; D019275:Radiopharmaceuticals; D012211:Rhenium